Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Stout

Showing results (431-440 of 439) with videos related to

Pageof 44
Sort By:
You have reached the last page of results.This site can display upto 439 results.
Psychiatry Research|June 3, 2008
Further development of YBOCS dimensions in the OCD Collaborative Genetics study: symptoms vs. categoriesAnthony Pinto, Benjamin D Greenberg, Marco A Grados, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Echo Research and Practice|February 21, 2025
Multi-societal expert consensus statement on the safe administration of ultrasound contrast agentsJordan B Strom, Andrew Appis, Richard G Barr, et al.
CA: a Cancer Journal for Clinicians|October 17, 2019
Exercise is medicine in oncology: Engaging clinicians to help patients move through cancerKathryn H Schmitz, Anna M Campbell, Martijn M Stuiver, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2011
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitorPatrick C May, Robert A Dean, Stephen L Lowe, et al.
Bioorganic & Medicinal Chemistry|December 2, 2019
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsLeonard L Winneroski, Jon A Erickson, Steven J Green, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.
Journal of Medicinal Chemistry|April 14, 2021
Defining Target Engagement Required for Efficacy <i>In Vivo</i> at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt)Charles W Lugar, Christian A Clarke, Richard Morphy, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2015
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansPatrick C May, Brian A Willis, Stephen L Lowe, et al.
Pageof 44

Showing results (431-440 of 439) with videos related to

Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 439 results.
Psychiatry Research|June 3, 2008
Further development of YBOCS dimensions in the OCD Collaborative Genetics study: symptoms vs. categoriesAnthony Pinto, Benjamin D Greenberg, Marco A Grados, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Echo Research and Practice|February 21, 2025
Multi-societal expert consensus statement on the safe administration of ultrasound contrast agentsJordan B Strom, Andrew Appis, Richard G Barr, et al.
CA: a Cancer Journal for Clinicians|October 17, 2019
Exercise is medicine in oncology: Engaging clinicians to help patients move through cancerKathryn H Schmitz, Anna M Campbell, Martijn M Stuiver, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 18, 2011
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitorPatrick C May, Robert A Dean, Stephen L Lowe, et al.
Bioorganic & Medicinal Chemistry|December 2, 2019
Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraintsLeonard L Winneroski, Jon A Erickson, Steven J Green, et al.
Journal of Medicinal Chemistry|June 3, 2021
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE InhibitorDavid L McKinzie, Leonard L Winneroski, Steven J Green, et al.
Journal of Medicinal Chemistry|April 14, 2021
Defining Target Engagement Required for Efficacy <i>In Vivo</i> at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt)Charles W Lugar, Christian A Clarke, Richard Morphy, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 23, 2015
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansPatrick C May, Brian A Willis, Stephen L Lowe, et al.
Pageof 44